Vanderbilt Network Lead Academic Participating Site for the NCTN

描述(申请人提供)：范德比尔特-英格拉姆癌症中心(VLCC)是范德比尔特大学内的一个基质癌症中心。24年来，VLCC试验一直是合作组系统的一部分，作为东方合作肿瘤组、妇科肿瘤组(GOG)和美国外科医学院肿瘤组(ACOSOG)的成员。在这一角色中，我们将我们的医生纳入领导角色，将我们的科学纳入临床试验，并将患者聚集到试验中。VLCC选择马里兰州的乔丹·柏林为PI，领导该机构将其科学、学术和患者资源整合到新的NCTN中的努力。他在临床试验和领导方面广泛参与了合作小组。他也是一位成功的导师。为了在医学学科和疾病利益之间保持广泛的代表性，成立了两个领导委员会。内部顾问委员会(LAB)确保赠款的最佳使用，如预算审查，确保多学科参与和参与整个NCTN，而NCTN执行委员会(NEC)执行诸如试验开始、累积和指导等业务职能。实验室和NEC都将致力于将VLCC科学整合到NCTN中。VLCC临床试验共享资源及其NCTN团队将确保监管和生物医学/放射学数据提交及时且高度准确。VLCC在合作小组中有着长期的领导能力，包括科学和管理方面的领导，将基础科学整合到临床试验中，并帮助初级教员进行试验开发。VLC为NCTN带来了巨大的优势，包括两个孢子资助，两个EDRN资助，一个世界级的成像科学研究所，先进的蛋白质组学能力和一个卓越的定量科学中心。我们的个性化癌症医学计划致力于回答具有挑衅性的问题B5(突变或表观遗传变化的发生顺序如何改变癌症表型或影响靶向治疗的疗效？)，并将耐药相关突变的数据带入临床试验。与之相辅相成的是MyCancerGenome网站，该网站不仅向医生提供癌症基因组学的最新信息，还为其肿瘤含有可操作的基因改变的患者提供试验。VLCC的科学家、学术领袖和初级研究人员组成的团队将为NCTN目标做出重大贡献，从而改善癌症患者的预后。

DESCRIPTION (provided by applicant): Vanderbilt-Ingram Cancer Center (VlCC) is a matrix cancer center within Vanderbilt University. VlCC trials been part of the cooperative group system for 24 years, as a member of the Eastern Cooperative Oncology Group, the Gynecologic Oncology Group (GOG) and the American College of Surgeons Oncology Group (ACOSOG). In this role, we have integrated our physicians into leadership roles and our science into the clinical trials and accrued patients into trials. The VlCC selected Jordan Berlin, MD, as PI to lead the efforts of the institution to integrate its scientific, academic and patient resourcs into the new NCTN. He has been involved extensively In the cooperative groups in both clinical trials and leadership. He has also been a successful mentor. To maintain a broad representation across medical disciplines and disease interests, two leadership boards were created. The internal advisory board (lAB) assures the optimum use of the grant such as budget review, assuring multidisciplinary involvement and participation throughout the NCTN while the NCTN Executive Committee (NEC) implements operational functions such as trial opening, accrual, and mentoring. Both the lAB and NEC will work to integrate VlCC science into the NCTN. The VlCC Clinical Trials Shared Resource and its NCTN team will ensure that regulatory and biospecimen/radiology data submissions are timely and highly accurate. VlCC has a long track record of leadership, both scientific and administrative, within the cooperative groups, integrating basic science into clinical trials and helping junior faculty in trial development. VlC brings great strengths to the NCTN including two SPORE grants, two EDRN grants, a world class Institute of Imaging Science, advanced capabilities in proteomics and a superb Center for Quantitative Sciences. Our Personalized Cancer Medicine Initiative is dedicated to answering Provocative Question B5 (How does the order in which mutations or epigenetic changes occur alter cancer phenotypes or affect the efficacy of targeted therapies?), and bringing the data from drug resistance-associated mutations into clinical trials. This is complemented by MyCancerGenome, a website that not only informs physicians on the latest in cancer genomics, but also the availability of trials for patients whose tumors harbor actionable genetic alterations The team of VlCC scientists, academic leaders and junior Investigators will significantly contribute to the NCTN goals and, as a result, improve the outcomes for cancer patients.